Literature DB >> 7525657

Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.

R Montironi1, C Magi-Galluzzi, G Muzzonigro, E Prete, M Polito, G Fabris.   

Abstract

AIMS: To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
METHODS: The morphology, including the mitotic activity, of 12 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for three months with CET was evaluated in haematoxylin and eosin stained sections and compared with an untreated age and stage matched control group.
RESULTS: A differential effect on the non-neoplastic prostate was observed. In fact, the transition zone of the treated prostate showed simplification of the glandular lobules: the ducts and acini were small without undulations of the epithelial border and with a prominent basal cell layer. Within the peripheral zone there was inconspicuous branching of the ducts and acini which looked dilatated and lined by flattened atrophic epithelium. Prostatic intraepithelial neoplasia occurred in scattered ducts and acini in the peripheral zone of 10 of the 12 patients. The epithelial cell lining showed a prominent basal cell layer. A certain degree of secretory cell type stratification was always present. However, crowding was less evident than in the untreated prostate because of cytoplasmic clearing and enlargement as a result of coalescence of vacuoles. The treated adenocarcinomas had neoplastic acini which looked small and shrunken, and areas of individual infiltrating tumour cells separated by abundant interglandular connective tissue. The secretory cells of the nonneoplastic, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma lesions had inconspicuous nucleoli, nuclear shrinkage, chromatin condensation, and cytoplasmic clearing. Apoptotic bodies were easily identifiable in all the cell layers. The lumina were rich in macrophages, sloughed secretory cells with degenerative features, and apoptotic bodies. Mitoses were not observed in any of the treated non-neoplastic prostate, prostatic intraepithelial neoplasia, or prostatic adenocarcinomas, whereas the mitotic frequency increased from non-neoplastic prostate through prostatic intraepithelial neoplasia up to prostatic adenocarcinomas in the untreated specimens.
CONCLUSIONS: CET before radical prostatectomy causes regressive epithelial changes together with enhanced apoptosis and blocked mitotic activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525657      PMCID: PMC502174          DOI: 10.1136/jcp.47.10.906

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  28 in total

1.  The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.

Authors:  C A Peters; P C Walsh
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

2.  Normal histology of the prostate.

Authors:  J E McNeal
Journal:  Am J Surg Pathol       Date:  1988-08       Impact factor: 6.394

3.  Reproducibility of mitotic counts and identification of mitotic figures in malignant glial tumors.

Authors:  R Montironi; Y Collan; M Scarpelli; S Sisti; G Barbatelli; A Carnevali; E Pisani; G M Mariuzzi
Journal:  Appl Pathol       Date:  1988

4.  Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate.

Authors:  H J de Voogt; B R Rao; A A Geldof; L J Gooren; F G Bouman
Journal:  Prostate       Date:  1987       Impact factor: 4.104

5.  Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining.

Authors:  W A Raymond; A S Leong; J W Bolt; J Milios; J S Jose
Journal:  J Pathol       Date:  1988-10       Impact factor: 7.996

6.  The present status of radical prostatectomy for stages A and B prostatic cancer.

Authors:  H J Jewett
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

7.  Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.

Authors:  P C Sogani; M R Vagaiwala; W F Whitmore
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

8.  Response of the benign hypertrophied prostate to treatment with an LHRH analogue.

Authors:  P F Keane; A G Timoney; E Kiely; G Williams; G Stamp
Journal:  Br J Urol       Date:  1988-08

9.  Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.

Authors:  A Zalatnai; J I Paz-Bouza; T W Redding; A V Schally
Journal:  Prostate       Date:  1988       Impact factor: 4.104

10.  Prostatic intra-epithelial neoplasia and early invasion in prostate cancer.

Authors:  D G Bostwick; M K Brawer
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

View more
  11 in total

1.  [Therapy induced regressive changes of prostate cancer].

Authors:  B Helpap; J Köllermann
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

2.  Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.

Authors:  R Montironi; M Valli; G Fabris
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

Review 3.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

Review 4.  Pathological changes in prostate lesions after androgen manipulation.

Authors:  R Montironi; C C Schulman
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

5.  Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.

Authors:  Z Kolár; P G Murray; K Scott; A Harrison; B Vojtĕsek; J Dusek
Journal:  Mol Pathol       Date:  2000-02

6.  Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.

Authors:  Matthew D Morse; Douglas G McNeel
Journal:  Hum Immunol       Date:  2010-03-05       Impact factor: 2.850

7.  Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis.

Authors:  R Skryma; P Mariot; X L Bourhis; F V Coppenolle; Y Shuba; F Vanden Abeele; G Legrand; S Humez; B Boilly; N Prevarskaya
Journal:  J Physiol       Date:  2000-08-15       Impact factor: 5.182

Review 8.  The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update.

Authors:  B G Helpap; D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes.

Authors:  Bruno Jim Rocca; Alessandro Ginori; Aurora Barone; Calogera Calandra; Filippo Crivelli; Giulia De Falco; Sara Gazaneo; Sergio Tripodi; Gabriele Cevenini; Maria Teresa del Vecchio; Maria Raffaella Ambrosio; Piero Tosi
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

Review 10.  Degarelix and its therapeutic potential in the treatment of prostate cancer.

Authors:  Christian Doehn; Martin Sommerauer; Dieter Jocham
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.